Plant‐derived pharmaceuticals for the developing world

Hefferon, Kathleen

doi:10.1002/biot.201300162

Cited by 50 publications

(22 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Plant-made subunit vaccines are heat stable, lack animal pathogen contamination and can be engineered to contain multiple antigens, such as those that are combined with subunits of cholera toxin (CT), for the protection of humans and animals against multiple infectious diseases (Davoodi-Semiromi et al, 2010;Hefferon, 2013;Kwon et al, 2013b;Scotti et al, 2010). It is possible to harvest and process plant material on a large scale.…”

Section: Introductionmentioning

confidence: 99%

Plant‐made oral vaccines against human infectious diseases—Are we there yet?

Chan

Daniell

2015

Plant Biotechnology Journal

129

131

View full text Add to dashboard Cite

Summary Although the plant-made vaccine field started three decades ago with the promise of developing low-cost vaccines to prevent infectious disease outbreaks and epidemics around the globe, this goal has not yet been achieved. Plants offer several major advantages in vaccine generation, including low-cost production by eliminating expensive fermentation and purification systems, sterile delivery and cold storage/transportation. Most importantly, oral vaccination using plant-made antigens confers both mucosal (IgA) and systemic (IgG) immunity. Studies in the past 5 years have made significant progress in expressing vaccine antigens in edible leaves (especially lettuce), processing leaves or seeds through lyophilization and achieving antigen stability and efficacy after prolonged storage at ambient temperatures. Bioencapsulation of antigens in plant cells protects them from the digestive system; the fusion of antigens to transmucosal carriers enhances efficiency of their delivery to the immune system and facilitates successful development of plant vaccines as oral boosters. However, the lack of oral priming approaches diminishes these advantages because purified antigens, cold storage/transportation and limited shelf life are still major challenges for priming with adjuvants and for antigen delivery by injection. Yet another challenge is the risk of inducing tolerance without priming the host immune system. Therefore, mechanistic aspects of these two opposing processes (antibody production or suppression) are discussed in this review. In addition, we summarize recent progress made in oral delivery of vaccine antigens expressed in plant cells via the chloroplast or nuclear genomes and potential challenges in achieving immunity against infectious diseases using cold-chain-free vaccine delivery approaches.

show abstract

Section: Introductionmentioning

confidence: 99%

Plant‐made oral vaccines against human infectious diseases—Are we there yet?

Chan

Daniell

2015

Plant Biotechnology Journal

129

131

View full text Add to dashboard Cite

show abstract

“…Plant-made pharmaceuticals, including vaccines, antibodies, research reagents and pharmaceutical proteins are attractive targets for molecular farming. 50,51 Agrobacteriummediated transformation represents an effective and widely used approach to introduce desirable genes into plants, and for fundamental studies of gene expression. In this study, CTB-LK was successfully expressed in the sunflower by Agrobacterium-mediated transformation.…”

Section: Discussionmentioning

confidence: 99%

Expression of cholera toxin B subunit–lumbrokinase in edible sunflower seeds–the use of transmucosal carrier to enhance its fusion protein's effect on protection of rats and mice against thrombosis

Guan

Chen

et al. 2014

Biotechnology Progress

View full text Add to dashboard Cite

Lumbrokinase (LK) is a group of serine proteases with strong fibrinolytic and thrombolytic activities and is useful for treating diseases caused by thrombus. Cholera toxin B subunit (CTB) has been widely used to facilitate antigen delivery by serving as an effective mucosal carrier molecule for the induction of oral tolerance. We investigate here the application of CTB as a transmucosal carrier in enhancing its fusion protein-LKs effect to protect rats against thrombosis. Thus, in this study, CTB-LK fusion gene separated by a furin cleavage site was expressed in seeds of Helianthus annuus L. The activity of recombinant protein in seeds of transgenic sunflower was confirmed by Western blot analysis, fibrin plate assays and GM1 -ganglioside ELISA. The thrombosis model of rats and mice revealed that the oral administration of peeled seeds of sunflower expressing CTB-LK had a more significant anti-thrombotic effect on animals compared with that administration of peeled seeds of sunflower expressing LK. It is possible to conclude that CTB can successfully enhance its fusion protein to be absorbed in rats or mice thrombosis model. The use of CTB as a transmucosal carrier in the delivery of transgenic plant-derived oral therapeutic proteins was supported. In addition, for the purpose of that recombinant CTB-LK was designed for oral administration, thus the expression of CTB-LK in edible sunflower seeds eliminated the need for downstream processing of proteins.

show abstract

“…Utilizing plants for the large-scale production of recombinant proteins is estimated to be 2-10 % the cost of using microbial platforms, and up to 1000-fold more cost-effective than mammalian platforms (Twyman et al 2003;Sharma and Sharma 2009). Production of heterologous proteins in plant cells is becoming commercially acceptable for human therapeutics (Langer 2010), vaccine antigens (Hefferon 2013), industrial enzymes (Broz et al 2013), and nutraceuticals (Maxmen 2012). The seed has emerged as one of the most prominent plant organs for the recombinant protein production.…”

Section: Introductionmentioning

confidence: 99%